tbuckley/cabot-search huggingface dataset:
miR-29b Mediates NF-κB Signaling in KRAS-Induced Non–Small Cell Lung Cancers
Authors: Stephanie Langsch, Ulrich Baumgartner, Stefan Haemmig, Cornelia Schlup, Stephan C. Schäfer, Sabina Berezowska, Gregor Rieger, Patrick Dorn, Mario P. Tschan, Erik Vassella
Journal: Cancer Research (2016)

Abstract A global understanding of miRNA function in EGFR signaling pathways may provide insights into improving the management of KRAS-mutant lung cancers, which remain relatively recalcitrant to treatment. To identify miRNAs implicated in EGFR signaling, we transduced bronchial epithelial BEAS-2B cells with retroviral vectors expressing KRASG12V and monitored miRNA expression patterns by microarray analysis. Through this approach, we defined miR-29b as an important target for upregulation by mutant KRAS in non–small cell lung cancers. Cell biologic analyses showed that pharmacologic inhibition of EGFR or MEK was sufficient to reduce levels of miR-29b, while PI3K inhibition had no effect. In KRASG12V-transduced BEAS-2B cells, introduction of anti-miR-29b constructs increased the sensitivity to apoptosis, arguing that miR-29b mediated apoptotic resistance conferred by mutant KRAS. Mechanistic investigations traced this effect to the ability of miR-29b to target TNFAIP3/A20, a negative regulator of NF-κB signaling. Accordingly, overexpression of an miR-29b–refractory isoform of TNFAIP3 restored NF-κB and extrinsic apoptosis, confirming that TNFAIP3 is a functionally relevant target of miR-29b. We also noted that miR-29b could confer sensitivity to intrinsic apoptosis triggered by exposure to cisplatin, a drug used widely in lung cancer treatment. Thus, miR-29b expression may tilt cells from extrinsic to intrinsic mechanisms of apoptosis. Overall, our results reveal a complexity in cancer for miR-29b, which can act as either an oncogene or tumor suppressor gene depending on signaling context. Cancer Res; 76(14); 4160–9. ©2016 AACR.
Parathyroid carcinoma and atypical parathyroid neoplasms in MEN1 patients; A clinico-pathologic challenge. The MD Anderson case series and review of the literature
Authors: Ioannis Christakis, Naifa L. Busaidy, Gilbert J. Cote, Michelle D. Williams, Samuel M. Hyde, Angelica M. Silva Figueroa, Lily Joy Kwatampora, Callisia N. Clarke, Wei Qiu, Jeffrey E. Lee, Nancy D. Perrier
Journal: International Journal of Surgery (2016)
Psychopharmacologic management of patients: a method for recording treatment decisions
Authors: D J Kupfer, T P Detre
Journal: American Journal of Psychiatry (1975)

The authors describe a drug treatment form they designed, the KDS-8, that is suitable for use in all types of treatment settings. An important feature is a checklist of treatable target symptoms, with categories of improvement, no change, or worsening. Changes in drug regimen and the clinician's reasons for them are noted. Among the advantages the authors cite are easy retrievability of drug treatment data and the forms suitability for use in audit procedures and research.
Breast cancer screening
Authors: J B Witcombe
Journal: BMJ (1988)

encountered similar cases to those described by Dr D Thompson and others (7 May, p 1309) in which initial radiographs showed only degenerative changes, and only incessant pain and a raised erythrocyte sedimentation rate gave the clue that this was more serious than osteoarthritis.Two patients who were subsequently found to have staphylococcal septicaemia and vertebral osteomyelitis gave a clear history of recent trauma -in one a fall down stairs and in the other a fall in her garden.Similar pitfalls exist when elderly patients presenting with back pain are found later to have spinal metastases or myeloma (this is more common than vertebral osteomyelitis).The authors do not.mention isotope bone scanning.This can often determine the site of the lesion when radiographs are not helpful and may show involvement of other parts of the skeleton that is not obvious clinically.
Abstract B35: Differences in extracellular vesicle nucleic acid content show promise as prostate cancer biomarkers
Authors: Helen Jankowski, Belinda Goldie, Joshua Brzozowski, Danielle Bond, Christopher Scarlett, Kathryn Skelding, Judith Weidenhofer
Journal: Cancer Research (2016)

Abstract Prostate cancer has one of the highest incidence rates of all cancers worldwide. Although 5-year survival rates are high, this is generally attributed to most prostate cancers either exhibiting a slow progression towards metastasis or being indolent. However current treatments for localized disease have devastating effects on quality of life and the biomarkers that are currently available are not accurate enough. This has resulted in many men with indolent disease being unnecessarily treated. Therefore, it is essential to identify new prognostic biomarkers that are accurate, sensitive and able to be tested for in non-invasive ways. Extracellular vesicles (EVs) have gained interest as a promising avenue for cancer biomarkers in recent years. EVs are small spherical shaped vesicles, which are secreted from their tissue of origin and contain high amounts of noncoding RNAs. EVs, from a panel of 20 prostate cell lines from normal, primary cancer or metastatic sites, were investigated by Affymetrix Human Transcriptome arrays (HTA 2.0). This enabled the identification of nucleic acids that contribute to the development of metastasis through comparison with EV and cellular function. EVs were collected from cell culture media devoid of supplements after 48 hours, by ultraconcentration. RNA was extracted with Trizol and evaluated using total RNA Agilent 2100 bioanalyzer chips. RNA was converted to labeled cDNA and hybridized to HTA 2.0 cassettes. Data was normalized using expression console and analyzed using transcriptome analysis console. Bioanalyzer results illustrated a unique RNA profile for each of the 20 cell lines. Preliminary analysis of nucleic acid content showed that the amount of mRNA, miRNA, snRNA, snoRNA, tRNA, and lncRNA packaged into EVs varies between cell lines further highlighting the differences observed with bioanalyzer profiles. Further several transcripts had significantly different abundance levels that discriminated between EVs released from cells of normal prostate, prostate cancer and metastatic origin, showing potential as biomarkers. Further analysis is ongoing to identify what mechanisms contribute to the differential packaging of nucleic acid into EVs in prostate cells and specific nucleic acid changes that could be used as novel biomarkers. Citation Format: Helen Jankowski, Belinda Goldie, Joshua Brzozowski, Danielle Bond, Christopher Scarlett, Kathryn Skelding, Judith Weidenhofer. Differences in extracellular vesicle nucleic acid content show promise as prostate cancer biomarkers. [abstract]. In: Proceedings of the AACR Special Conference on Noncoding RNAs and Cancer: Mechanisms to Medicines ; 2015 Dec 4-7; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2016;76(6 Suppl):Abstract nr B35.
<i>Salmonella enterica</i>Aortitis
Authors: Masao Takagi, Mikiro Kato
Journal: New England Journal of Medicine (2016)

A 66-year-old man presented with a 1-month history of fever and 4 days of hoarseness. His temperature was 38.7°C. The peripheral-blood leukocyte count was elevated, and a chest radiograph showed enlargement of the aortic arch, with deviation of the trachea to the right side.
Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study
Authors: Jack R W Brownrigg, Cian O Hughes, David Burleigh, Alan Karthikesalingam, Benjamin O Patterson, Peter J Holt, Matthew M Thompson, Simon de Lusignan, Kausik K Ray, Robert J Hinchliffe
Journal: The Lancet Diabetes & Endocrinology (2016)
The current status of behavioral psychotherapy: theory and practice
Authors: I M Marks
Journal: American Journal of Psychiatry (1976)

Behavioral psychotherapy has become one of the definitive treatments available for the relief of psychiatric suffering. Although hardly a panacea for all ills, the behavioral approach is the treatment of choice for certain selected problems. Behavioral methods make their contribution in the context of general psychiatric management and often must be used in conjunction with other treatment. The theoretical and practical aspects of behavioral psychotherapy have changed a great deal over the past few years and continue to evolve rapidly. Although useful molecular theories are emerging to guide the discipline, no global theory is likely to be satisfactory in the foreseeable future.
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Authors: Rinath Jeselsohn, William T. Barry, Ilenia Migliaccio, Chiara Biagioni, Jin Zhao, Jonas De Tribolet-Hardy, Cristina Guarducci, Martina Bonechi, Naomi Laing, Eric P. Winer, Myles Brown, Angelo Di Leo, Luca Malorni
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Fulvestrant is an estrogen receptor (ER) antagonist and an approved treatment for metastatic estrogen receptor–positive (ER+) breast cancer. With the exception of ER levels, there are no established predictive biomarkers of response to single-agent fulvestrant. We attempted to identify a gene signature of response to fulvestrant in advanced breast cancer. Experimental Design: Primary tumor samples from 134 patients enrolled in the phase III CONFIRM study of patients with metastatic ER+ breast cancer comparing treatment with either 250 mg or 500 mg fulvestrant were collected for genome-wide transcriptomic analysis. Gene expression profiling was performed using Affymetrix microarrays. An exploratory analysis was performed to identify biologic pathways and new signatures associated with response to fulvestrant. Results: Pathway analysis demonstrated that increased EGF pathway and FOXA1 transcriptional signaling is associated with decreased response to fulvestrant. Using a multivariate Cox model, we identified a novel set of 37 genes with an expression that is independently associated with progression-free survival (PFS). TFAP2C, a known regulator of ER activity, was ranked second in this gene set, and high expression was associated with a decreased response to fulvestrant. The negative predictive value of TFAP2C expression at the protein level was confirmed by IHC. Conclusions: We identified biologic pathways and a novel gene signature in primary ER+ breast cancers that predicts for response to treatment in the CONFIRM study. These results suggest potential new therapeutic targets and warrant further validation as predictive biomarkers of fulvestrant treatment in metastatic breast cancer. Clin Cancer Res; 22(23); 5755–64. ©2016 AACR.
Real or media-mediated outbreak of coxsackie infections in 2002 in Greece?
Authors: M Exindari, G Gioula, D Raptis, V Mavroidi, E Bouzia, V Kyriazopoulou
Journal: Eurosurveillance (2005)

The purpose of this study was to provide evidence about the existence of a coxsackie B outbreak in Greece in 2002 by comparing data of laboratory confirmed coxsackie B recent infections in northern Greece between 1998-2001 with data from 2002. The infections were confirmed serologically, using the indirect immunofluorescence method detecting IgM antibodies for coxsackie B1-B6 viruses. Sera from 2701 patients residents of northern Greece who were suspected to be suffering from coxsackie B virus infections were examined: 2056 between 1998 and 2001, and 645 in 2002. The comparison between the results of laboratory confirmed cases and data available at the laboratory between the two periods showed that: The total number of patients examined per year was higher in 2002 (645 versus an annual average of 514 in 1998-2001). The proportion of laboratory confirmed recent infections was lower in 2002 (27.8% versus 32.7%) and the estimated incidence was 0.66/10,000 for 2002 and 0.32-0.84/10,000 for 1998-2001. The age distribution differed: the proportions of cases in children versus cases in adults were reversed in 2002 compared with 1998-2001, with a higher proportion among children in 2002. The difference between the two periods was statistically significant. Children aged 3-5 years were the age group most affected in 2002. Seasonal distribution remained the same for both periods (peaks in spring and autumn). In 2002, three fatal cases occurred in April, but no deaths were reported in 1998-2001. The clinical syndromes involved also differed: cases of respiratory infections, mainly pneumonia, rose from 5.75% to 24.3% in children in 2002 and cases of myopericarditis rose in adults from 13% in 1998-2001 to 29.5% in 2002. The last finding, combined with the involvement of the media (because of the three fatal cases) and the panic in the general public that followed suggested that an outbreak had occurred, but we conclude that there was no outbreak.
Response to sodium lactate infusion in alcoholics with panic attacks
Authors: D S Cowley, C F Jensen, D Johannessen, L Parker, S R Dager, R D Walker
Journal: American Journal of Psychiatry (1989)

The authors studied the response to sodium lactate infusion of 12 alcoholics with a history of panic attacks, 10 alcoholics without a history of panic attacks, and 16 nonalcoholic patients with panic disorder. The rate of lactate-induced panic was significantly higher in alcoholics with panic attacks than in alcoholics without panic attacks. Alcoholics with panic attacks were similar to nonalcoholic patients with panic disorder in their response to lactate. These findings support the specificity of lactate-induced panic for panic states and suggest that panic attacks in alcoholics resemble those in nonalcoholics. Lactate infusion may prove useful in the diagnosis of panic disorder in alcoholics.
Tricyclic antidepressants for children with cancer
Authors: B Pfefferbaum-Levine, K Kumor, A Cangir, M Choroszy, E A Roseberry
Journal: American Journal of Psychiatry (1983)

Eight depressed children with cancer had a rapid clinical response to low doses of imipramine or amitriptyline. Because of the many variables affecting cancer patients, the mechanism by which tricyclic antidepressant treatment produced this response is unclear.
Adverse events following vaccination in the French armed forces: An overview of surveillance conducted from 2002 to 2010
Authors: A Mayet, R Haus-Cheymol, E A Bouaiti, C Decam, F Simon, A Mérens, A Spiegel, J B Meynard, X Deparis, R Migliani
Journal: Eurosurveillance (2012)

French military personnel are subject to a compulsory vaccination schedule. The aim of this study was to describe vaccine adverse events (VAE) reported from 2002 to 2010 in armed forces. VAE are routinely surveyed by the military Centre for epidemiology and public health. For each case, military practitioners fill a notification form, providing patient characteristics, clinical information and vaccines administered. For this study, VAE following influenza A(H1N1)pdm09 vaccination were excluded. Among the 473 cases retained, 442 (93%) corresponded to non-severe VAE,including local, regional and systemic events, while 31 corresponded to severe VAE, with two leading to significant disability. The global VAE reporting rate (RR) was 14.0 per 100,000 injections. While stationary from 2002 to 2008, the RR increased from 2009. The most important observations were a marked increase of VAE attributed to Bacillus Calmette-Guérin (BCG) vaccine from 2005 to 2008, a high RR observed with the inactivated diphtheria-tetanus (toxoids)-poliovirus vaccine combined with acellular pertussis vaccine (dTap-IPV) from 2008 and an increase in RR for seasonal influenza vaccine VAE in 2009. Our RR for severe VAE (1.1 VAEper 100,000) appears comparable with rates observed among United States civilians and military personnel. The increase observed from 2009 could be partly explained by the influenza A(H1N1)pdm09 pandemic which increased practitioner awareness towards VAE. In conclusion, the tolerance of the vaccines used in French armed forces appears acceptable.
Platelet-Mediated Mechanical Tensile Force Influences ADAMTS13 Localization and Regulation Of Thrombus Development At The Site Of Platelet Accumulation
Authors: Yasuaki Shida, Laura L. Swystun, Christine Brown, Jeff Mewburn, Kate Sponagle, Ozge Danisment, Jacob Riches, Christine Hough, David Lillicrap
Journal: Blood (2013)
Inhibition of 2-Fluorenamine-Induced Mutagenesis in &lt;italic&gt;Salmonella typhimurium&lt;/italic&gt; by Vitamin A&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: M B Baird, L S Birnbaum
Journal: JNCI Journal of the National Cancer Institute (1979)

Vitamin A alcohol (retinol) completely Inhibited the mutagenicity of the carcinogen 2-fluorenamine (2-FA) in Salmonella typhimurium TA98 when the mutagen was activated by liver microsomes from CFN rats. The mutagenicity of 2-FA activated by 9,000×g rat liver supernatant S9 was inhibited by retinol to a lesser degree. The decline in the number of his+ revertants was not an artifact due to bacterial killing, inasmuch as retinol was not toxic to the bacteria at levels that totally inhibited mutagenesis by 2-FA. Mutagenesis induced by adrlamycin, an antibiotic that does not require metabolic activation for mutagenic potential, was unaffected by vitamin A. These results indicate that retlnoids inhibit the metabolic activation of some chemical carcinogens to forms that can interact with DNA. Our findings are consistent with the hypothesis that retinoids may exert anticancer activity by inhibiting carcinogen activation, thereby inhibiting tumor induction, in addition to the more widely accepted role of retinoids in modulating the proliferation of eplthelially derived neoplasms.
Inadequate plasma concentrations in some high-dose methadone maintenance patients
Authors: F S Tennant
Journal: American Journal of Psychiatry (1987)

The author studied 18 heroin addicts who had been maintained on 80 mg/day of methadone and who abused drugs or alcohol. His findings suggest that in some cases of aberrant methadone metabolism, the dose can be raised to achieve plasma concentrations adequate to eliminate drug and alcohol abuse.
A psychoanalyst reports at mid-career
Authors: J E Gedo
Journal: American Journal of Psychiatry (1979)

The author states that the current pessimistic impression of the potential of psychoanalysis as a therapy is largely due to the inclusion of a disproportionate number of inexperienced analysts in reports on groups of practitioners. To correct this bias, he summarizes his own experience of two decades as a full-time psychoanalyst, describing his successful analyses as well as his unsuccessful attempts. He concludes that the satisfaction of commitment to a psychoanalytic career comes from the fact that it confirms the usefulness of the analytic method as a means to assist others to achieve personal growth and to illuminate human mental life.
Depressive phenomenology in North and South American patients
Authors: J I Escobar, J Gomez, V B Tuason
Journal: American Journal of Psychiatry (1983)

The authors assessed patients newly admitted to two North American health centers and one South American (Colombian) center according to a standardized protocol, with a structured interview, a symptom checklist, and a depression scale. The patients were suffering from major depressive disorders with endogenous features. There was an impressive similarity in symptoms of depression across cultures, supporting the idea of a universal core depressive syndrome. However, somatization indexes, psychomotor components of depression, and levels of psychopathology differed between U.S. and Colombian samples. The authors offer a general discussion of potential determinants of these cross-cultural differences.
Dialysis for schizophrenia: an uncontrolled study of 11 patients
Authors: S C Scheiber, I Cohen, H Yamamura, R Noval, L Beutler
Journal: American Journal of Psychiatry (1981)

The authors evaluated hemodialysis as a treatment for schizophrenia in an uncontrolled study of 11 patients. Eight men and two women with chronic schizophrenia who had responded poorly to conventional treatments or who had sought alternate treatments received three dialyses weekly for 3 weeks; 1 additional subject dropped out after eight treatments. MMPI, Psychiatric Status Scale, and Inpatient Multidimensional Psychiatric Scale scores were obtained before, immediately following, and at intervals after the nine treatments. Preliminary results, including 1-month follow-up, suggest that subjects with pretreatment anxiety and depression improved. No endorphins were discovered in the dialysate.
The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL)
Authors: S. A. Gregory, J. P. Leonard, S. J. Knox, A. D. Zelenetz, J. Armitage, M. Kaminiski
Journal: Journal of Clinical Oncology (2004)

6732 Background: The Bexxar (tositumomab and iodine I 131 tositumomab [B]) therapeutic regimen yields high rates of complete and durable responses in pts with relapsed/refractory LG NHL. Methods: The safety of B therapy was reviewed for 995 pts with relapsed/refractory LG NHL, including 230 pts in 5 clinical trials and 765 pts in an expanded access program (EAP). Demographics and risk factors were similar for both groups except that pts from EAP were less heavily pretreated (median, 2 vs 4 prior therapies) and more frequently received Rituximab (56% vs 17%). All adverse events (AEs) occurring within 13 wks of treatment were reported, regardless of relationship to study drug. Median follow-up was 24 mo (range, 0.1 - 118 mo). Results: Most frequent hematologic (heme) AEs were grade (gr) 3/4 neutropenia (41%), thrombocytopenia (37%), and anemia (12%), requiring supportive care in 27% of pts (G-CSF, 12%; erythropoietin, 10%; platelet transfusions 12%; packed RBCs, 16%). Bleeding events occurred in 7% of pts (2% gr 3/4) and serious infection in 5%. Significant (P < .001) predictors of gr 3/4 heme toxicity were number of prior therapies, baseline blood counts, prior fludarabine, and degree of bone marrow (BM) involvement. Nonheme gr 3/4 AEs occurred in < 5% of pts. Infusions were well tolerated (2% gr 3/4 infusion AEs). Delayed toxicities included HAMA responses (cumulative incidence, 9.8% at 2 yr; 10.1% at 5 yr) and hypothyroidism (cumulative incidence, 8.7% at 2 yr; 16.6% at 5 yr), and 35 pts developed MDS/AML after B therapy. A masked independent review of BM and peripheral blood (Bennett et al. Blood. 2003;102:30a. Abstr 91) showed that the overall incidence of MDS/AML was 2.1% (95% CI = 1.3, 3.2%) with an annualized incidence of 1.1%/yr (95% CI = 0.7, 1.6%/yr). Conclusions: The most common AEs were prolonged cytopenias, but rates of heme sequelae were low. The data do not suggest an increased risk of MDS/AML over that seen in pts heavily pretreated with leukemogenic therapies. These data suggest that the risks associated with B therapy are outweighed by the clinical benefits in pts with relapsed/refractory LG NHL. No significant financial relationships to disclose.
Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease
Authors: Francesca Vinchi, Milene Costa da Silva, Giada Ingoglia, Sara Petrillo, Nathan Brinkman, Adrian Zuercher, Adelheid Cerwenka, Emanuela Tolosano, Martina U. Muckenthaler
Journal: Blood (2015)
Common and Rare Egfr Mutations in Non-Small Cell Lung Cancer
Authors: A.D. Campos Parra, A.F. Cardona, L. Corrales, R. Sánchez Reyes, J. Rodríguez, C.A. Vargas, H. Carranza, J. Otero, R. Rosell, O. Arrieta
Journal: Annals of Oncology (2014)